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ABSTRACT
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. 
Numerous studies have shown that microRNAs (miRNAs) could play a role in this 
disease. Nowadays, more than 2500 miRNAs have been described, that regulate more 
than 50% of genes, including those involved in B-cell maturation, differentiation 
and proliferation. Genetic variants in miRNAs can alter their own levels or function, 
affecting their target gene expression, and then, may affect ALL risk. Therefore, 
the aim of this study was to determine the role of miRNA genetic variants in 
B-ALL susceptibility. We analyzed all variants in pre-miRNAs (MAF > 1%) in two 
independent cohorts from Spain and Slovenia and inferred their functional effect 
by in silico analysis. SNPs rs12402181 in miR-3117 and rs62571442 in miR-3689d2 
were associated with ALL risk in both cohorts, possibly through their effect on MAPK 
signalling pathway. These SNPs could be novel markers for ALL susceptibility.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most 
common childhood malignancy and a leading cause of 
death due to disease in children [1, 2]. The genetic basis 
of ALL susceptibility has been supported by its association 
with certain congenital disorders [3] and, more recently, 
by several genome-wide association studies (GWAS). 
These GWAS identified common variants in ARID5B, 
IKZF1, CEBPE and CDKN2A influencing ALL risk in 
children of European descent [3–8], widely validated 
[9–14]. While most association studies are mainly focused 
on the coding regions, which correspond only to 1.5% of 
the entire genome, many SNPs found in these GWAS are 
located in non coding regions. 
MiRNAs are non-coding RNAs that regulate gene 
expression at the post-transcriptional level by binding 
to the 3ʹ untranslated region (UTR) of a target mRNA, 
leading to its translation inhibition or degradation [15]. 
Through this mechanism, miRNAs regulate more than 
50% of human genes, having an enormous impact on the 
function of any cell [16], including B-lymphocytes. 
It has been widely shown that miRNAs regulate 
B-cell maturation and function, controlling B-cell receptor 
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(BCR) signalling, B-cell migration/adhesion, cell–cell 
interactions in immune niches, and the production and 
class-switching of immunoglobulins [17, 18]. They 
also contribute to the regulation of important signalling 
pathways such as tyrosine kinase and Ras signalling [18], 
whose deregulation has been demonstrated in ALL [19]. 
In fact, recent studies have found more than 200 miRNAs 
deregulated in pediatric patients diagnosed with B-cell 
precursor acute lymphoblastic leukemia (B-ALL) [20–23]. 
All these data show the role of miRNAs in pediatric B-ALL.
Genetic variations in miRNAs can alter their function 
affecting their target genes expression. These variants can 
modify miRNA expression levels if they are located in the 
pre-miRNA, or the mRNA-miRNA binding if they are 
located in the seed region. Nowadays, several works have 
already described polymorphisms in miRNAs associated 
with the susceptibility to different types of cancer [24, 25]. 
Despite all these evidences, only four studies analyzing 
the involvement of SNPs in miRNAs in the risk of ALL 
have been performed, and interestingly, all of them found 
significant findings [26–29]. Hasani and colleagues found 
rs2910164 in miR-146a associated with ALL susceptibility in 
a Iranian population of 75 children diagnosed with ALL [26]. 
Tong and colleagues found association between rs11614913 
in miR-196a-2 and rs4938723 in miR-34b and ALL risk in 
a Chinese population of 574 pediatric ALL patients [27, 29]. 
Recently, our group found association between rs12803915 
in miR-612, rs3746444 in miR-499 and rs10061133 in miR-
449b and B-ALL risk in a Spanish cohort of 213 children 
[28]. Of note is the fact that, although a relatively low 
number of SNPs in miRNAs were analyzed in relation to 
B-ALL susceptibility, significant results were found.
Considering all these data and that nowadays the 
number of annotated miRNAs has increased substantially 
up to approximately 2500 miRNAs [30], the aim of this 
study was to determine the role of the currently described 
SNPs in miRNAs in the risk of B-ALL. For this aim, we 
analyzed all variants in pre-miRNAs genes with a minor 
allele frequency higher than 1% in two independent 
cohorts of Spanish and Slovenian origin. The putative 
functional implication of significant variants was inferred 
by in silico analysis.
RESULTS
Genotyping results
Genotyping analyses were performed in 310 patients 
with B-ALL (231 from Spain and 79 from Slovenia) and 
434 unrelated healthy controls (338 from Spain and 96 
from Slovenia). Successful genotyping was achieved for 
718 of 744 DNA samples (96.5%), 217 children with 
B-ALL and 330 controls from the Spanish cohort and 75 
children with B-ALL and 96 controls from the Slovenian 
cohort (Table 1). From the total of 213 SNPs, 135 SNPs 
(63.4%) were included in the association analysis after 
eliminating SNPs with genotyping failures (< 80%), 
monomorphic in our population or with deviations from 
HWE in controls (Supplementary Table 1). Genotyping 
was validated using TaqMan OpenArray technology in 
175 samples and 15 SNPs and the concordance between 
both platforms was 99.8% (Supplementary Table 2).
Genotype association study of B-ALL
We analyzed all the SNPs in both populations 
separately. From the total of 135 SNPs, we found two 
SNPs in two miRNAs, rs12402181 in miR-3117-3p and 
rs62571442 in miR-3689d2, significantly associated with 
B-ALL risk in both Spanish and Slovenian population 
(Supplementary Table 3). Both SNPs remained significant 
after multivariate logistic regression to account for the 
possible confounding effect of sex.
The AA genotype of rs12402181 in miR-3117-
3p displayed a 1.44-fold increased risk of B-ALL (95% 
CI: 1.01–2.08; p = 0.047) under the log-additive genetic 
model (GG vs AG vs AA) in the Spanish population. 
The same effect was observed in the Slovenian cohort 
(OR: 2.01; 95% CI: 1.02–3.95; p = 0.041). When both 
populations were analyzed together, they showed the same 
trend increasing the p value (OR: 1.53; 95% CI: 1.12–
2.09; P = 0.006). In the analysis of allele frequencies in 
both populations, the minor allele A showed a 1.51-fold 
increased risk of B-ALL (95% CI: 1.11–2.05; p = 0.007).
The second SNP was rs62571442 in miR-3689d2. 
The CT/CC genotype showed a 1.48-fold increased risk 
of B-ALL (95% CI: 1.02–2.15; p = 0.039) in the Spanish 
cohort. In the Slovenian cohort, a higher p value was 
observed (OR: 3.57; 95% CI: 1.57–8.12; p = 0.001). When 
both populations were analyzed together, they showed the 
same tendency (OR: 1.31; 95% CI: 1.06–1.60; p = 0.011). 
In the analysis of allele frequencies in both populations, 
the minor allele C showed a 1.31-fold increased risk of 
B-ALL (95% CI: 1.06–1.6; p = 0.012).
When we analyzed the Spanish cohort 
independently, other 13 SNPs in 13 miRNAs were 
significantly associated with B-ALL risk. None of these 
13 SNPs were replicated in the Slovenian population 
(Supplementary Table 4). In the Slovenian cohort, other 
11 SNPs in 10 miRNAs showed association with B-ALL 
risk and none of these 11 SNPs were replicated in the 
Spanish population (Supplementary Table 5). All the SNPs 
remained significantly associated with ALL risk after 
multivariate logistic regression to account for the possible 
confounding effect of sex. None of the SNPs reached 
statistical significance when FDR correction was applied.
Bioinformatic analysis
miRNAs secondary structures prediction
We analyzed in silico the energy change (|ΔΔG|) 
and the secondary structures modifications of the 
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SNPs associated with B-ALL risk in both populations 
(rs12402181 in miR-3117-3p and rs62571442 in miR-
3689d2). 
The SNP rs12402181 is located in the seed region 
of miR-3117-3p. The change from G to A allele did not 
show either an energy change or change in the secondary 
structure. On the other hand, rs62571442, located in the 
pre-miRNA of miR-3689d2, showed an energy change 
from -31.2 kcal/mol for the T allele to -30.0 kcal/mol for 
the risk allele C (1.2 kcal/mol). This SNP also produced 
an evident change in the secondary structure (Figure 1).
Pathway analysis
In order to evaluate the pathways that could be 
affected by the miRNAs with the most significant SNPs, 
we first searched the target genes using miRWalk database 
and next, we performed a pathway enrichment analysis by 
using the ConsensusPathDB web tool. 
Among the ten most significant pathways for miR-
3117-3p, we found the mitogen-activated protein kinase 
(MAPK) signalling pathway over-represented (p-value of 
4.9 × 10-7) (Supplementary Table 6). In this pathway, miR-
3117-3p targeted up to 24 genes (Supplementary Table 7). 
Moreover, seven out of these ten enriched pathways were 
related to Ras signalling cascade, which is one of the 
MAPK pathways (Supplementary Table 6). 
Regarding miR-3689d2, six out of ten most 
significant pathways were also related with Ras signalling, 
and this miRNA targeted up to 32 genes involved in 
MAPK signalling (Supplementary Tables 8 and 9). When 
we analyzed the putative target genes of both miRNAs 
together, the association for MAPK signalling pathway 
increased up to p = 5.75 × 10-13, with both miRNAs 
targeting up to 55 genes of the pathway. Moreover, eight 
out of the top ten pathways were related with Ras cascade 
(Figure 2 and Supplementary Table 10).
DISCUSSION
In the current study, rs12402181 in miR-3117 
and rs62571442 in miR-3689d2 showed statistically 
significant association with B-ALL risk in the two 
independent cohorts analyzed in this study, Spanish and 
Slovenian population. Our results point to a putative role 
of SNPs in miRNAs in B-ALL susceptibility.
The SNP rs12402181 in miR-3117-3p was 
associated with an increased risk of developing B-ALL 
under the additive model, A allele being the risk allele. 
This result was observed in the Spanish (p = 0.047) and 
the Slovenian population (p = 0.041). The association 
increased when both populations were analyzed 
together (p = 0.006). These results support the idea that 
rs12402181 A allele could represent a risk allele of low 
penetrance for B-ALL independently of the population 
studied. Rs12402181 is located in the seed region of miR-
3117-3p, a miRNA expressed in B-ALL [20], therefore, 
the change of the G allele for the A allele could affect the 
accurate recognition of its target mRNA sequences. The 
loss of binding could increase the expression of its target 
Table 1: Study population
Spanish cohort Slovenian cohort
 Patients Controls Patients Controls
No. of individuals 231 338 79 96
Mean age ± SE, y 4.04 ± 3.61 57.8 ± 28.1 4.65 ± 5.41 44.5 ± 9.4
Sex*
Males, n (%) 128 (55.7) 157 (46.4) 41 (51.9) 58 (60.4)
Females, n (%)  102 (44.3) 181 (53.6) 38 (48.1) 38 (39.6)
Genetic alterations#
Hyperdiploid 56 (24.2) - 9 (11.4) -
ETV6-RUNX1 37 (16.0) - 12 (15.2) -
MLL 13 (5.6) - 4 (5.1) -
BCR-ABL 6 (2.6) - 1 (1.3) -
E2A-PBX1 6 (2.6) - - -
Hypodiploid 2 (0.9) - 1 (1.3) -
Other 1 (0.4) - 6 (7.6) -
No alteration 95 (41.1) - 48 (60.8) -
Not available 21 (9.1) - 0 -
SE: standard error, y: years *There is no datum for one patient of the Spanish cohort. #Six patients have more than one 
alteration in the Spanish cohort and two of the patients have more than one alteration in the Slovenian cohort.
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genes. Among the target genes of miR-3117-3p, in silico 
analysis showed that genes of MAPK signalling pathway 
are over-represented (Figure 2), including mainly genes 
of the MAPK/ERK family or classical pathway [31–33]. 
Interestingly, the genes predicted to be targeted by miR-
3117-3p are in the first steps of the cascade (CACNG1, 
CACNG8, PDGFR, GRB2, SOS1 and RAS), which in turn 
could produce the deregulation of the following steps. 
Aberrant expression of this pathway is a major and highly 
prevalent oncogenic event in many human cancers [34], 
including childhood ALL [35, 36]. In summary, failed 
recognition between miR-3117-3p and its targets due 
to the change of the rs12402181 G allele to the A allele 
in the seed region could contribute to leukemogenesis 
by leading to an aberrant activation of the RAS-MAPK 
pathway.
The second SNP, rs62571442 in miR-3689d2, was 
associated with an increased risk of B-ALL under the 
additive model, C allele being the risk allele. This result 
was observed in the Spanish cohort (p = 0.039), as well 
as in the Slovenian population (p = 0.001), indicating that 
this SNP could be a general marker for B-ALL. The C > T 
change in this SNP, located in the pre-miRNA sequence, 
modified the secondary structure and induced a positive 
energy change of 1.2 kcal/mol for the C risk allele. The 
hairpin structure changed from stable (U:A) to unstable 
status (C:A). When the SNP decreases the stability, the 
production of mature miRNA is reduced, which in turn 
may increase target gene expression [37]. In the pathway 
analysis of miR-3689d2, six out of the top ten enriched 
pathways were again related to the aforementioned Ras 
signalling. Therefore, a decreased expression of this 
miRNA could increase the expression of RAS-MAPK 
pathway genes. 
When pathways analysis for miR-3117-3p and 
miR-3689d2 were performed together, eight out of the 
ten first pathways were related to RAS-MAPK signalling, 
and the association obtained was higher. Therefore, both 
miRNAs could contribute to the activation of this pathway 
in a synergistic way: on the one hand, because of the 
loss of target recognition due to the A allele of the SNP 
rs12402181 in the seed region of miR-3117-3p, and on the 
other hand, because of the reduction in mature levels of 
miR-3689d2 due to the risk allele C of rs62571442 in the 
hairpin structure. These results were found in two different 
populations, therefore, they could be considered as general 
markers of B-ALL susceptibility. It would be interesting to 
study these associations in other populations.
Figure 1: Secondary structures of the miRNAs with SNPs associated with B-ALL risk, predicted by the miRNA SNP 
tool.
Oncotarget22911www.oncotarget.com
This study has some limitations that might be 
addressed, such as the relatively high failure rate in 
genotyping technique (63.4%). However, this high chance 
of failure was accepted from the beginning of the study, 
because despite the predicted low score for genotyping, 
no other design option to amplify the polymorphisms in 
question was possible. Moreover, these results did not 
reach a significant p-value when FDR correction was 
applied, but we would like to emphasize that both SNPs 
were significant in two independent cohorts. Another 
possible weakness is the known inaccuracy of the miRNA 
target prediction algorithms of the databases used [38, 39]. 
In conclusion, rs12402181 in miR-3117-3p and 
rs62571442 in miR-3689d2 could be involved in B-ALL 
susceptibility through their effect on the regulation of 
MAPK signalling-related pathways. 
MATERIALS AND METHODS
Study participants
A total of 310 Caucasian children diagnosed with 
B-ALL and 434 unrelated healthy controls were included 
in this study (Table 1). The Spanish cohort consisted of 
231 children diagnosed with B-ALL between 2000 and 
2011 in the Pediatric Oncology Units of four Spanish 
hospitals (University Hospital Cruces, University 
Hospital Donostia, University Hospital La Paz and 
University Hospital Miguel Servet) and 338 unrelated 
healthy individuals. The Slovenian cohort consisted of 79 
Caucasian children diagnosed with B-ALL between 1993 
and 2009, at the Department of Hematology and Oncology 
of the University Children’s Hospital Ljubljana and 96 
unrelated healthy individuals. 
Data were collected objectively, blinded to 
genotypes, from the patients’ medical files. Sex and 
age data were systematically recorded from the clinical 
records (Table 1). Informed consent was obtained from 
all participants, or from their parents prior to sample 
collection. The study was approved by the ethics 
committees (PI2014039 and 62/07/03) and was carried 
out according to the Declaration of Helsinki.
Selection of genes and polymorphisms
We selected all the SNPs in pre-miRNAs with a 
MAF > 0.01 in European/Caucasian populations described 
in the databases until May 2014. We decided to include 
all miRNAs due to the fact that they can regulate a wide 
range of genes that are not completely defined. Therefore, 
any miRNA could be implicated in the regulation of genes 
affecting B-ALL risk. Of a total of 1910 SNPs in 969 
miRNAs found at the moment of the study, we included 
all the SNPs with a MAF > 0.01, a total of 213 SNPs in 
206 pre-miRNAs (Supplementary Table 1). The SNP 
selection was performed using miRNA SNiPer (www.
integratomics-time.com/miRNA-SNiPer/), NCBI (http://
www.ncbi.nlm.nih.gov/snp/) and literature review. 
Genotype analyses
Genomic DNA was extracted from remission 
peripheral blood or bone marrow (with < 5% blast cells) 
as previously described [40]. DNA was quantified using 
PicoGreen (Invitrogen Corp., Carlsbad, CA). 
Figure 2: Genes of the MAPK signalling pathway targeted by miR-3117-3p and miR-3689d2 (adapted from KEGG 
database).
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For each sample, 400 ng of DNA were genotyped 
using the GoldenGate Genotyping Assay with Veracode 
technology according to the published Illumina protocol. 
Data were analyzed with GenomeStudio software for 
genotype clustering and calling. Duplicate samples and 
CEPH trios (Coriell Cell Repository, Camden, NJ) were 
genotyped across the plates. SNPs showing Mendelian 
allele-transmission errors or showing discordant genotypes 
were excluded from the analysis.
In order to validate the genotyping, 175 samples 
and 15 SNPs were genotyped using TaqMan OpenArray 
Genotyping technology according to the published 
Applied Biosystems protocol and analyzed using Taqman 
Genotyper software (Applied Biosystems, Carlsbad, CA). 
Statistical analysis 
To identify any deviation from Hardy-Weinberg 
equilibrium (HWE) for the healthy controls, a χ2 test was 
used. The association between genetic polymorphisms 
in cases and controls was also evaluated using the χ2 or 
Fisher’s exact test. The effect sizes of the associations 
were estimated by the odds ratio from univariate 
logistic regression and multivariate logistic regression 
to account for the possible confounding effect of sex. 
The most significant test among codominant (major 
allele homozygotes vs. heterozygotes and major allele 
homozygotes vs. minor allele homozygotes), dominant 
(major allele homozygotes vs. heterozygotes + minor allele 
homozygotes), recessive (major allele homozygotes + 
heterozygotes vs. minor allele homozygotes), and additive 
(doses-dependent effect: major allele homozygotes vs. 
heterozygotes vs. minor allele homozygotes) genetic 
models was selected. The results were adjusted for 
multiple comparisons by the False Discovery Rate (FDR) 
[41]. In all cases the significance level was set at 5%. 
Analyses were performed using R v2.11 software. 
Bioinformatic analysis
miRNAs secondary structures prediction
The RNAfold web tool (http://rna.tbi.univie.ac.at) 
was used to calculate the minimum free energy (MFE) 
secondary structures and to predict the most stable 
secondary structures of the miRNAs with statistically 
significant SNPs.
Gene targets selection and pathways analysis
MiRWalk [32] (http://zmf.umm.uni-heidelberg.de/
apps/zmf/mirwalk2/) database was used to select miRNA 
targets. Targets predicted by at least 6 different algorithms 
provided by miRWalk were selected. Enriched pathway 
analyses of putative target genes were determined with 
ConsensusPath database (CPdB) (http://consensuspathdb.
org/) [31] using the over-representation analysis module. 
Gene lists were analyzed against the default collection of 
KEGG [33], Reactome [42] and BioCarta (http://cgap.nci.
nih.gov/Pathways/BioCarta_Pathways) pathway databases. 
A conservative p-value cutoff (0.0001) was used. 
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